Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Flynn Pharma Ltd
Alton House, 4 Herbert Street, Dublin 2, Republic of Ireland,
Telephone: +44 (0)1438 727822
Fax: +44 (0)1438 727805
WWW: http://www.flynnpharma.com
Medical Information Direct Line: +44 (0)1438 727822
Medical Information e-mail: medinfo@flynnpharma.com
Customer Care direct line: +44 (0)1773 510 123
Medical Information Fax: +44 (0)1438 727805

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 04/09/2009
SPC Axid Capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 04/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01-Oct-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
In section 4.8 (undesirable effects) information on blood dyscrasias has been expanded
Updated on 19/03/2008 and displayed until 04/09/2009
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Updating section 9 and 10 of the SPC
Updated on 09/01/2008 and displayed until 19/03/2008
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   08/2005
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Update to section 9 and 10
Updated on 30/09/2005 and displayed until 09/01/2008
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MA number
  • Change to section 10 (date of (partial) revision of the text
Updated on 26/04/2004 and displayed until 30/09/2005
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 10 (date of (partial) revision of the text
Updated on 17/09/2001 and displayed until 26/04/2004
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 10 (date of (partial) revision of the text
Updated on 15/08/2001 and displayed until 17/09/2001
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 01/06/2000 and displayed until 15/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 01/06/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  nizatidine